Heron Therapeutics is trading at $0.33, down 10.05%, amid biotech-sector pressure. - No fresh company-specific announcement explaining the October 6 decline was found; no confirmed company-specific catalyst was identified, and the drop was sharper than the sector move. - At 12:25 p.m. EDT, biotech ETF XBI was down 2.94% while major U.S. indexes were higher, suggesting weakness was concentrated in biotech.